Fergal (MSc)

Environmental Health and Safety Manager at Zymeworks Inc. - Vancouver, British Columbia, CA

Fergal (MSc)'s Colleagues at Zymeworks Inc.
Sue SHRM

Manager, Total Rewards

Contact Sue SHRM

Diana Papove

Corporate Communications Manager

Contact Diana Papove

Patricia Tan

Specialist, Staffing Operations

Contact Patricia Tan

Alex CPA

Manager, Compliance Internal Controls

Contact Alex CPA

Senthil PhD

Associate Director, Head of Validation

Contact Senthil PhD

Lisa Boyken

Principal Statistician

Contact Lisa Boyken

Joan Li

Senior Principal Statistical Programmer

Contact Joan Li

View All Fergal (MSc)'s Colleagues
Fergal (MSc)'s Contact Details
HQ
(604) 678-1388
Location
Company
Zymeworks Inc.
Fergal (MSc)'s Company Details

Zymeworks Inc.

Vancouver, British Columbia, CA • 500 - 999 Employees
BioTech/Drugs

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is advancing a robust pipeline of wholly-owned product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibodies. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. Additionally, Zymeworks’ therapeutic platforms have been further leveraged through strategic partnerships.

Clinical-Stage Biopharmaceutical Company Clinical Trials Solid Tumors
Details about Zymeworks Inc.
Frequently Asked Questions about Fergal (MSc)
Fergal (MSc) currently works for Zymeworks Inc..
Fergal (MSc)'s role at Zymeworks Inc. is Environmental Health and Safety Manager.
Fergal (MSc)'s email address is ***@zymeworks.com. To view Fergal (MSc)'s full email address, please signup to ConnectPlex.
Fergal (MSc) works in the BioTech/Drugs industry.
Fergal (MSc)'s colleagues at Zymeworks Inc. are Sue SHRM, Diana Papove, Patricia Tan, Alex CPA, Senthil PhD, Lisa Boyken, Joan Li and others.
Fergal (MSc)'s phone number is (604) 678-1388
See more information about Fergal (MSc)